Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363670 · ClinicalTrials.gov registry record · Phase 2
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
A Phase 2 study, sponsored by ARS Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT05363670 is a Phase 2 study that has completed, run by ARS Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT05363670, a Phase 2 study, has completed, sponsored by ARS Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Interventions
- DRUG Placebo
- DRUG ARS-1
- DRUG Albuterol MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2024-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363670
The ClinicalTrials.gov registry entry for NCT05363670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARS Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05363670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363670 about?
NCT05363670 is a clinical study titled "Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma". ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
What is the current status of trial NCT05363670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-07-28. Estimated completion is 2024-02-02.
What interventions are being tested in trial NCT05363670?
The interventions under investigation include: Placebo (DRUG), ARS-1 (DRUG), Albuterol MDI (DRUG).
Who is sponsoring clinical trial NCT05363670?
This trial is sponsored by ARS Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.